Peter M. Voorhees, MD, discusses the 5-year follow-up results from the CARTITUDE-1 trial of ciltacabtagene autoleucel for the ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Patients with drug-resistant multiple myeloma find early success with a new CAR T therapy, a recent study finds ...

CAR T-cell therapy targeting B-cell maturation antigen (BCMA) has become a game changer for patients with relapsed or refractory multiple myeloma. In 2021, the FDA approved idecabtagene vicleucel (ide ...

Peter M. Voorhees, MD, shares key insights from the 2025 American Society of Clinical Oncology Annual Meeting, specifically in the multiple myeloma space.

CAR T-cell therapy is used to treat blood cancers, including multiple myeloma. This article discusses CAR T-cell therapy for multiple myeloma, how it works, and what you can expect during treatment.

Refractory multiple myeloma is a type of blood cancer that doesn't get better with treatment or that stops responding to treatment. You may need to try different combinations of treatments to slow ...

Multiple myeloma is considered incurable, but a third of patients in a Johnson & Johnson clinical trial have lived without detectable cancer for years after facing certain death.

The first off-the-shelf (allogeneic) CAR T cell therapy for multiple myeloma appears safe and effective. The therapy, which targets a protein called BCMA, could allow people to get treated more ...

A clinical trial released encouraging safety results for a universal, ready-made version of CAR T therapy for multiple myeloma.

At Fred Hutchinson Cancer Center, we offer comprehensive myeloma treatment from a team of experts who are dedicated to treating patients with this rare cancer.